235 related articles for article (PubMed ID: 24204904)
1. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.
Wöhrle S; Weiss A; Ito M; Kauffmann A; Murakami M; Jagani Z; Thuery A; Bauer-Probst B; Reimann F; Stamm C; Pornon A; Romanet V; Guagnano V; Brümmendorf T; Sellers WR; Hofmann F; Roberts CW; Graus Porta D
PLoS One; 2013; 8(10):e77652. PubMed ID: 24204904
[TBL] [Abstract][Full Text] [Related]
2. SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.
Wei D; Goldfarb D; Song S; Cannon C; Yan F; Sakellariou-Thompson D; Emanuele M; Major MB; Weissman BE; Kuwahara Y
Mol Cancer Res; 2014 Nov; 12(11):1574-85. PubMed ID: 25009291
[TBL] [Abstract][Full Text] [Related]
3. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
Kuwahara Y; Wei D; Durand J; Weissman BE
Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
[TBL] [Abstract][Full Text] [Related]
4. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.
Caramel J; Medjkane S; Quignon F; Delattre O
Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027
[TBL] [Abstract][Full Text] [Related]
5. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.
Jagani Z; Mora-Blanco EL; Sansam CG; McKenna ES; Wilson B; Chen D; Klekota J; Tamayo P; Nguyen PT; Tolstorukov M; Park PJ; Cho YJ; Hsiao K; Buonamici S; Pomeroy SL; Mesirov JP; Ruffner H; Bouwmeester T; Luchansky SJ; Murtie J; Kelleher JF; Warmuth M; Sellers WR; Roberts CW; Dorsch M
Nat Med; 2010 Dec; 16(12):1429-33. PubMed ID: 21076395
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors.
McKenna ES; Tamayo P; Cho YJ; Tillman EJ; Mora-Blanco EL; Sansam CG; Koellhoffer EC; Pomeroy SL; Roberts CW
Cell Cycle; 2012 May; 11(10):1956-65. PubMed ID: 22544318
[TBL] [Abstract][Full Text] [Related]
7. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Darr J; Klochendler A; Isaac S; Eden A
Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
[TBL] [Abstract][Full Text] [Related]
8. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
Darr J; Klochendler A; Isaac S; Geiger T; Eden A
Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.
Kim KH; Roberts CW
Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101
[TBL] [Abstract][Full Text] [Related]
10. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
[TBL] [Abstract][Full Text] [Related]
11. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus.
Kia SK; Gorski MM; Giannakopoulos S; Verrijzer CP
Mol Cell Biol; 2008 May; 28(10):3457-64. PubMed ID: 18332116
[TBL] [Abstract][Full Text] [Related]
12. Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.
Algar EM; Muscat A; Dagar V; Rickert C; Chow CW; Biegel JA; Ekert PG; Saffery R; Craig J; Johnstone RW; Ashley DM
PLoS One; 2009; 4(2):e4482. PubMed ID: 19221586
[TBL] [Abstract][Full Text] [Related]
13. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.
Wang X; Sansam CG; Thom CS; Metzger D; Evans JA; Nguyen PT; Roberts CW
Cancer Res; 2009 Oct; 69(20):8094-101. PubMed ID: 19789351
[TBL] [Abstract][Full Text] [Related]
14. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
15. Loss of Snf5 Induces Formation of an Aberrant SWI/SNF Complex.
Sen P; Luo J; Hada A; Hailu SG; Dechassa ML; Persinger J; Brahma S; Paul S; Ranish J; Bartholomew B
Cell Rep; 2017 Feb; 18(9):2135-2147. PubMed ID: 28249160
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation.
Isakoff MS; Sansam CG; Tamayo P; Subramanian A; Evans JA; Fillmore CM; Wang X; Biegel JA; Pomeroy SL; Mesirov JP; Roberts CW
Proc Natl Acad Sci U S A; 2005 Dec; 102(49):17745-50. PubMed ID: 16301525
[TBL] [Abstract][Full Text] [Related]
17. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice.
Roberts CW; Galusha SA; McMenamin ME; Fletcher CD; Orkin SH
Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13796-800. PubMed ID: 11095756
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.
Li T; Wang J; Liu P; Chi J; Yan H; Lei L; Li Z; Yang B; Wang X
Oncotarget; 2017 Jul; 8(29):47269-47283. PubMed ID: 28521298
[TBL] [Abstract][Full Text] [Related]
19. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.
Nakayama RT; Pulice JL; Valencia AM; McBride MJ; McKenzie ZM; Gillespie MA; Ku WL; Teng M; Cui K; Williams RT; Cassel SH; Qing H; Widmer CJ; Demetri GD; Irizarry RA; Zhao K; Ranish JA; Kadoch C
Nat Genet; 2017 Nov; 49(11):1613-1623. PubMed ID: 28945250
[TBL] [Abstract][Full Text] [Related]
20. Pathology and diagnosis of SMARCB1-deficient tumors.
Margol AS; Judkins AR
Cancer Genet; 2014 Sep; 207(9):358-64. PubMed ID: 25246033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
